Detail Information of Post-Translational Modifications
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0122 Transporter Info | ||||
Gene Name | SLC17A9 | ||||
Transporter Name | Solute carrier family 17 member 9 | ||||
Gene ID | |||||
UniProt ID | |||||
Post-Translational Modification of This DT | |||||
Overview of SLC17A9 Modification Sites with Functional and Structural Information | |||||
Sequence |
MQPPPDEARR DMAGDTQWSR PECQAWTGTL LLGTCLLYCA RSSMPICTVS MSQDFGWNKK
EAGIVLSSFF WGYCLTQVVG GHLGDRIGGE KVILLSASAW GSITAVTPLL AHLSSAHLAF MTFSRILMGL LQGVYFPALT SLLSQKVRES ERAFTYSIVG AGSQFGTLLT GAVGSLLLEW YGWQSIFYFS GGLTLLWVWY VYRYLLSEKD LILALGVLAQ SRPVSRHNRV PWRRLFRKPA VWAAVVSQLS AACSFFILLS WLPTFFEETF PDAKGWIFNV VPWLVAIPAS LFSGFLSDHL INQGYRAITV RKLMQGMGLG LSSVFALCLG HTSSFCESVV FASASIGLQT FNHSGISVNI QDLAPSCAGF LFGVANTAGA LAGVVGVCLG GYLMETTGSW TCLFNLVAII SNLGLCTFLV FGQAQRVDLS STHEDL |
||||
PTM type |
X-Phosphorylation
X: Amino Acid
|
Phosphorylation |
|||||
---|---|---|---|---|---|
Serine |
1 PTM Phenomena Related to This Residue | Click to Show/Hide the Full List | |||
PTM Phenomenon 1 |
Have the potential to influence SLC17A9 | [1] | |||
Role of PTM |
Potential impacts | ||||
Modified Residue |
Serine |
Modified Location |
207 | ||
Experimental Method |
Co-Immunoprecipitation | ||||
Detailed Description |
Phosphorylation at SLC17A9 Serine 207 has the potential to affect its expression or activity. | ||||
References | |||||
---|---|---|---|---|---|
1 | Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.